Xtl Biopharmaceuticals Stock Number Of Shares Shorted
| XTLB Stock | ILS 6.30 0.20 3.08% |
XTL Biopharmaceuticals fundamentals help investors to digest information that contributes to XTL Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of XTL Stock. The fundamental analysis module provides a way to measure XTL Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XTL Biopharmaceutica stock.
XTL |
XTL Biopharmaceuticals Company Number Of Shares Shorted Analysis
XTL Biopharmaceutica's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, XTL Biopharmaceuticals has 0.0 of outstending shares currently sold short by investors. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Number Of Shares Shorted (which currently averages 0.0) industry. This indicator is about the same for all Israel stocks average (which is currently at 0.0).
Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
XTL Fundamentals
| Return On Equity | 0.38 | |||
| Return On Asset | -0.1 | |||
| Current Valuation | 61.84 M | |||
| Shares Outstanding | 514.21 M | |||
| Shares Owned By Insiders | 16.20 % | |||
| Price To Earning | 558.33 X | |||
| EBITDA | (940 K) | |||
| Net Income | 435 K | |||
| Cash And Equivalents | 5.06 M | |||
| Cash Per Share | 0.01 X | |||
| Current Ratio | 51.07 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (1.05 M) | |||
| Beta | 1.03 | |||
| Market Capitalization | 236.53 K |
About XTL Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XTL Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XTL Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XTL Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in XTL Stock
XTL Biopharmaceutica financial ratios help investors to determine whether XTL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTL with respect to the benefits of owning XTL Biopharmaceutica security.